RCE — Recce Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- AU$118.23m
- AU$118.53m
- AU$7.70m
- 14
- 26
- 42
- 15
Annual income statement for Recce Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.96 | 3.18 | 4.43 | 5.24 | 7.7 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 15.5 | 14.2 | 17.3 | 22.1 | 28 |
| Operating Profit | -13.5 | -11 | -12.9 | -16.8 | -20.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13.5 | -11 | -13.1 | -17.7 | -21.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13.5 | -11 | -13.1 | -17.7 | -21.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.5 | -11 | -13.1 | -17.7 | -21.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.5 | -11 | -13.1 | -17.7 | -21.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.085 | -0.062 | -0.073 | -0.099 | -0.09 |